The estimated Net Worth of Michael L Kranda is at least $291 mil dollars as of 16 March 2015. Michael Kranda owns over 2,500 units of PTC Therapeutics Inc stock worth over $72,349 and over the last 11 years Michael sold PTCT stock worth over $218,815.
Michael has made over 2 trades of the PTC Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Michael sold 2,500 units of PTCT stock worth $182,025 on 16 March 2015.
The largest trade Michael's ever made was selling 2,500 units of PTC Therapeutics Inc stock on 16 March 2015 worth over $182,025. On average, Michael trades about 922 units every 92 days since 2014. As of 16 March 2015 Michael still owns at least 2,242 units of PTC Therapeutics Inc stock.
You can see the complete history of Michael Kranda stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O VULCAN VENTURES INCORPORATED,, 505 FIFTH AVENUE, SUITE 900, SEATTLE, WA, 98104.
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over $50,602,930 worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth $57,374,337 . The most active insiders traders include Suisse/ Credit, Adam Koppel y Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $888,748. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth $77,191.
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
PTC Therapeutics Inc executives and other stock owners filed with the SEC include: